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SUMMARY 
 
Background. The exact etiology and the mechanisms of inflammatory bowel disease 
(IBD) are still unknown. Recent advances in the understanding of the 
pathophysiological conditions of IBD have provided new therapeutic targets. In the last 
decades animal studies suggested the role of ion transport mechanisms in intestinal 
colonic crypts in the pathogenesis of ulcerative colitis (UC). Despite the comprehensive 
animal studies, there are only scarce available data on the ion transporter activities of 
the normal and inflamed human colon. The aim of our study was to characterize the 
segmental differences of ion transport mechanisms (namely Na+/H+ exchangers [NHE1-
3], the epithelial sodium channel [ENaC] and the SLC26A3 Cl-/HCO3- exchanger 
downregulated in adenoma [DRA]) in human colonic epithelial cells and to examine the 
activities of these transporters in UC. We also evaluated the efficacy of the infliximab 
induction therapy in Crohn’s disease (CD) and assessed the safety and long-term 
applicability of infliximab treatment in patients with IBD. Materials and methods. 128 
healthy controls and 69 patients suffering from active UC were involved in the first part 
of the study. Primary colonic crypts were isolated from human biopsy and surgical 
samples. The expressional and functional characteristics of NHE1-3, ENaC and DRA 
were determined by using fluorescence, patch clamp and real time RT PCR techniques. 
In the second part of the study one year review was undertaken of all CD patients who 
achieved remission or fistula closure with 3 infusions of infliximab. We evaluated the 
clinical response, the estimated CD Activity Index (CDAI), the number of draining 
fistulae, the dosages of steroid and immunosuppressive drugs at 6 and 12 months after 
the last infusion, and the needs for hospitalization and surgical intervention during this 
period. For the evaluation of the long term applicability and safety of infliximab 
therapy, data of 127 IBD patients were analyzed. A total of 733 infusions were 
administered, the mean number of infliximab infusions was 5.8/patient. The mean 
length of follow up was 2.3 years. Results. The activities of electroneutral (via NHE3) 
and the electrogenic Na+ absorption (via ENaC) are in inverse ratio to each other in the 
proximal and distal colon. No significant differences were detected in the activity of 
NHE2 in different segments of the colon. Surface cell Cl-/HCO3- exchange is more 
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active in the distal vs. the proximal part of the colon. Importantly, both sodium and 
chloride absorptions are damaged in UC, whereas, NHE1 which has been shown to 
promote immune response is up-regulated by 6-fold. Infliximab induction therapy 
without retreatment resulted in a beneficial effect lasting for at least 1 year in 44% of 
the patients. 57.9% of the patients with luminal disease remained in steroid-free 
complete remission, while the fistulas persisted closed in only 35.5% of the patients. 
12.6% of the patients had 31 episodes of acute, 5.5% patients had 9 episodes of delayed 
infusion reaction. 68.8% of those with acute reaction were on concomitant 
immunomodulator and/or corticosteroid treatment. Listeria meningoencephalitis, sepsis, 
pulmonary tuberculosis and lymphoma in two cases were the most severe infectious 
complications. The mortality rate was 3.1%. The beneficial effect of infliximab was also 
confirmed by two unusual cases. Infliximab maintenance therapy led to complete 
mucosal healing in severe refractory pouchitis and rectal instillation of infliximab was 
also successful in severe proctitis. Discussion. The experimental results of our 
comprehensive human study demonstrated the differences in the various ion transport 
mechanisms between the different parts of the colon. We also revealed that both sodium 
and chloride transport is damaged, whereas NHE1 is up-regulated in UC. With selective 
inhibition of NHE1 and/or stimulation of NHE3, ENaC and DRA our results may open 
up new therapeutical targets in UC. Infliximab induction therapy alone may result in 
sustained remission mainly in patients with luminal CD, while fistulizing disease 
requires maintenance infliximab therapy. The rate of serious adverse events is less than 
5%, confirming infliximab therapy safe in the long-term. 
 
 
  
 
 
 
 
 
